CN107865821B - 一种预防或治疗脉络膜新生血管形成的制剂 - Google Patents
一种预防或治疗脉络膜新生血管形成的制剂 Download PDFInfo
- Publication number
- CN107865821B CN107865821B CN201710872258.4A CN201710872258A CN107865821B CN 107865821 B CN107865821 B CN 107865821B CN 201710872258 A CN201710872258 A CN 201710872258A CN 107865821 B CN107865821 B CN 107865821B
- Authority
- CN
- China
- Prior art keywords
- eye drop
- freeze
- active ingredient
- dried powder
- acetic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- 208000005590 Choroidal Neovascularization Diseases 0.000 title claims abstract description 24
- 206010060823 Choroidal neovascularisation Diseases 0.000 title claims abstract description 24
- XZXHXSATPCNXJR-ZIADKAODSA-N nintedanib Chemical group O=C1NC2=CC(C(=O)OC)=CC=C2\C1=C(C=1C=CC=CC=1)\NC(C=C1)=CC=C1N(C)C(=O)CN1CCN(C)CC1 XZXHXSATPCNXJR-ZIADKAODSA-N 0.000 claims abstract description 25
- 229960004378 nintedanib Drugs 0.000 claims abstract description 25
- 239000004480 active ingredient Substances 0.000 claims abstract description 21
- 239000000463 material Substances 0.000 claims abstract description 10
- 150000003839 salts Chemical class 0.000 claims abstract description 4
- 239000012453 solvate Substances 0.000 claims abstract description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 44
- 239000003889 eye drop Substances 0.000 claims description 33
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 20
- 229930195725 Mannitol Natural products 0.000 claims description 20
- 239000000594 mannitol Substances 0.000 claims description 20
- 235000010355 mannitol Nutrition 0.000 claims description 20
- 229930006000 Sucrose Natural products 0.000 claims description 17
- 239000005720 sucrose Substances 0.000 claims description 17
- 229940012356 eye drops Drugs 0.000 claims description 16
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 15
- 239000000843 powder Substances 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 13
- 239000006172 buffering agent Substances 0.000 claims description 11
- 239000003755 preservative agent Substances 0.000 claims description 10
- 230000002335 preservative effect Effects 0.000 claims description 10
- 239000000243 solution Substances 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 230000003204 osmotic effect Effects 0.000 claims description 7
- 238000005192 partition Methods 0.000 claims description 7
- 238000004458 analytical method Methods 0.000 claims description 6
- 239000003963 antioxidant agent Substances 0.000 claims description 6
- 230000003078 antioxidant effect Effects 0.000 claims description 6
- 239000002738 chelating agent Substances 0.000 claims description 6
- 239000004094 surface-active agent Substances 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 5
- 238000004806 packaging method and process Methods 0.000 claims description 5
- 230000001954 sterilising effect Effects 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims description 3
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 3
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical group [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 3
- 238000007710 freezing Methods 0.000 claims description 3
- 230000008014 freezing Effects 0.000 claims description 3
- 238000000859 sublimation Methods 0.000 claims description 3
- 230000008022 sublimation Effects 0.000 claims description 3
- 230000003139 buffering effect Effects 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 abstract description 3
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 239000000872 buffer Substances 0.000 description 16
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 14
- 239000013641 positive control Substances 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 13
- 241000700159 Rattus Species 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 238000004128 high performance liquid chromatography Methods 0.000 description 10
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 108091008605 VEGF receptors Proteins 0.000 description 5
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 5
- 206010064930 age-related macular degeneration Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 208000002780 macular degeneration Diseases 0.000 description 5
- 229940124676 vascular endothelial growth factor receptor Drugs 0.000 description 5
- 206010067484 Adverse reaction Diseases 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- 108010081667 aflibercept Proteins 0.000 description 3
- 239000007979 citrate buffer Substances 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 3
- 229960001597 nifedipine Drugs 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 208000006069 Corneal Opacity Diseases 0.000 description 2
- 108091008794 FGF receptors Proteins 0.000 description 2
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 2
- 108091008606 PDGF receptors Proteins 0.000 description 2
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- 229960002833 aflibercept Drugs 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 231100000269 corneal opacity Toxicity 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 2
- 229940076783 lucentis Drugs 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 230000000649 photocoagulation Effects 0.000 description 2
- 229960002633 ramucirumab Drugs 0.000 description 2
- 229960003876 ranibizumab Drugs 0.000 description 2
- 239000000790 retinal pigment Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 125000000185 sucrose group Chemical group 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000032436 Retinal depigmentation Diseases 0.000 description 1
- 208000000208 Wet Macular Degeneration Diseases 0.000 description 1
- 150000001243 acetic acids Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940120638 avastin Drugs 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- -1 eye washes Substances 0.000 description 1
- 229940051306 eylea Drugs 0.000 description 1
- 238000011354 first-line chemotherapy Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000008720 membrane thickening Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- CPMDPSXJELVGJG-UHFFFAOYSA-N methyl 2-hydroxy-3-[N-[4-[methyl-[2-(4-methylpiperazin-1-yl)acetyl]amino]phenyl]-C-phenylcarbonimidoyl]-1H-indole-6-carboxylate Chemical compound OC=1NC2=CC(=CC=C2C=1C(=NC1=CC=C(C=C1)N(C(CN1CCN(CC1)C)=O)C)C1=CC=CC=C1)C(=O)OC CPMDPSXJELVGJG-UHFFFAOYSA-N 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000000065 osmolyte Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical compound [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- XPFJYKARVSSRHE-UHFFFAOYSA-K trisodium;2-hydroxypropane-1,2,3-tricarboxylate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].[Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O XPFJYKARVSSRHE-UHFFFAOYSA-K 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明涉及一种预防或治疗脉络膜新生血管形成的制剂,所述的制剂包括活性成分,以及药学上可接受的辅料,所述的活性成分为尼达尼布及其盐或溶剂合物。本发明的制剂成本低,使用便捷,对预防和治疗脉络膜新生血管形成等眼部疾病具有显著的治疗作用。
Description
技术领域
本发明属于药物制剂领域,涉及一种预防或治疗脉络膜新生血管形成的制剂。
背景技术
年龄相关性黄斑变性,也称老年黄斑变性(Age related macular degeneration,AMD),大多发生于45岁以上,其患病率随年龄的增长而增高,是当前中老年人致盲的重要疾病。该病分为干性(也叫非渗出性)和湿性(也叫渗出性)两种类型,干性主要为脉络膜毛细血管萎缩,玻璃膜增厚和视网膜色素上皮萎缩引起的黄斑区萎缩变性;湿性主要为玻璃膜的破坏,脉络膜血管侵入视网膜下构成脉络膜新生血管(choroidal neovascularization,CNV),进而发生黄斑区视网膜色素上皮下或神经上皮下浆液性或出血性的盘状脱离,最终成为机化瘢痕。据临床观察萎缩型也可转变为渗出型。
VEGF(血管内皮生长因子受体)是经典的血管生成信号通路,可用于治疗多种实体瘤和湿性年龄相关性黄斑变性(AMD),FDA已经批准的针对VEGF单抗或融合蛋白有贝伐珠单抗(Avastin)、雷珠单抗(Lucentis)、阿柏西普(Eylea)、雷莫芦单抗(Cyramza),我国自主研发的康柏西普(商品名:朗沐)已于2013年上市。
以上产品多为注射使用,雷珠单抗(Lucentis)和阿柏西普(Eylea)为玻璃体注射剂,之后我国自主研发的康柏西普也沿用玻璃体注射剂的思路。康柏西普虽然疗效显著,但顺应性差,治疗价格高昂,使用不便且成本很高。
尼达尼布,即3-Z-[1-(4-(N-((4-甲基-哌嗪-1-基)-甲基羰基)-N-甲基-氨基)-苯胺基)-1-苯基-亚甲基]-6-甲氧基羰基-2-二氢吲哚酮,化合物结构如下:
尼达尼布是一种新型的血管生成抑制剂,可同时作用于血管生成过程中涉及的3种关键受体家族:血管内皮生长因子受体(VEGFR)、血小板源性生长因子受体(PDGFR)以及成纤维细胞生长因子受体(FGFR)。尼达尼布已被FDA和EMA批准上市,用于治疗特发性肺纤维化(IPF),也被EMA批准联合多西他赛在一线化疗之后应用于组织学诊断为腺癌的、局部晚期或转移性或局部复发性非小细胞肺癌(NSCLC)成年患者。目前还未见将尼达尼布应用于治疗脉络膜新生血管的相关文献报道。此外,因为尼达尼布本身的溶解性和稳定性问题,国外已上市的和国内正在研发的尼达尼布制剂均以固体口服剂居多。而对于眼部疾病来说,固体形式的口服制剂的效果明显弱于眼睛局部给药的效果,且安全性更低。
发明内容
本发明的目的是提供一种对脉络膜新生血管形成具有显著的预防或治疗作用且顺应性好、适于眼部局部给药且使用方便的制剂。
为解决以上技术问题,本发明采取如下技术方案:
一种预防或治疗脉络膜新生血管形成的制剂,所述的制剂包括活性成分,以及药学上可接受的辅料,所述的活性成分为尼达尼布及其盐或溶剂合物,所述的制剂为滴眼剂、眼膏剂、洗眼剂、脂质体、微囊或微球。
本发明中,所述的活性成分为尼达尼布或乙磺酸尼达尼布。
根据一个实施方式,所述的滴眼剂为液体制剂,所述的辅料包括缓冲剂、渗透压调节剂以及选择性的包括粘度调节剂、防腐剂、表面活性剂、螯合剂、稳定剂、抗氧剂中的一种或多种。
优选地,所述的缓冲剂为醋酸缓冲剂,所述的渗透压调节剂为甘露醇和/或蔗糖;所述的活性成分的质量百分比浓度为0.005%~10%;所述的醋酸缓冲剂的浓度为5~20mM,所述的醋酸缓冲剂以pH3.5~6.0的醋酸缓冲液的形式投料;所述的甘露醇和/或蔗糖的质量百分比浓度为1%~10%。
进一步优选地,所述的活性成分的质量浓度为0.01%~0.1%。
进一步优选地,所述的缓冲剂的浓度为5~15mM,最优选为10mM。
进一步优选地,当所述的渗透压调节剂为甘露醇时,所述的甘露醇的质量浓度为3%~5%;当所述的渗透压调节剂为蔗糖时,所述的蔗糖的质量浓度为7%~9%。
进一步地,所述的液体制剂还包括质量浓度为0.001%~0.01%的所述的防腐剂。
优选地,所述的防腐剂为苯扎氯铵。
优选地,所述的液体制剂的pH为4.5~9.0。
进一步优选地,所述的液体制剂的pH为5.0~6.0。
更优选地,所述的液体制剂的pH为5.0~5.5。
根据另一个实施方式,所述的滴眼剂包括独立包装的含有所述的活性成分的冻干粉和复溶液,所述的冻干粉中的辅料包括赋形剂以及选择性的包括粘度调节剂、防腐剂、表面活性剂、螯合剂、稳定剂、抗氧剂中的一种或多种;所述的复溶液中的辅料包括缓冲剂以及选择性的包括粘度调节剂、防腐剂、表面活性剂、螯合剂、稳定剂、抗氧剂中的一种或多种。
优选地,所述的赋形剂为甘露醇和/或蔗糖,所述的缓冲剂为醋酸缓冲剂;
所述的冻干粉中所述的活性成分与所述的甘露醇和/或蔗糖的质量比为1:50~200;
所述的复溶液的pH为4.5~9,所述的醋酸缓冲剂的浓度为5~20mM。
进一步优选地,当所述的赋形剂为甘露醇时,所述的冻干粉中所述的活性成分与所述的甘露醇的质量比为1:70~90;当所述的赋形剂为蔗糖时,所述的冻干粉中所述的活性成分与所述的蔗糖的质量比为1:150~170。
进一步优选地,所述的缓冲剂的浓度为5~15mM,最优选为10mM。
进一步优选地,所述的复溶液的pH为5.0~6.0。
更优选地,所述的复溶液的pH为5.0~5.5。
优选地,所述的冻干粉的pH为5.0~6.0,进一步优选为5.0~5.5。
根据一个具体实施方式,所述的冻干粉的制备方法包括依次进行的如下步骤:
步骤(1)、将所述的活性成分、所述的赋形剂和水搅拌溶解,然后过滤除菌分装;
步骤(2)、预冻阶段:设置隔板温度为-10~-50℃,保持1~6小时;
步骤(3)、升华干燥阶段:设置隔板温度为0~-40℃,前箱压力1~200Pa,保持5~30小时;
步骤(4)、解析干燥阶段:设置隔板温度为0~40℃,前箱压力1~200Pa,保持5~30小时;
步骤(5)、解析干燥阶段后,真空压塞,得到所述的冻干粉。
具体地,所述的制剂避光保存于2~8℃条件下。
由于以上技术方案的实施,本发明与现有技术相比具有如下优点:
本发明通过对制剂的组分及配比的改进,使得在保证活性成分不析出的前提下,使得制剂中活性成分的浓度高,从而保证对脉络膜新生血管形成等眼部疾病的预防或治疗效果,本发明的制剂适于眼部局部给药且使用方便,顺应性好,成本低。
附图说明
附图1为加醋酸缓冲液的开始时的HPLC谱图;
附图2为加醋酸缓冲液的结束时的HPLC谱图;
附图3为加柠檬酸缓冲液的开始时的HPLC谱图;
附图4为加柠檬酸缓冲液的结束时的HPLC谱图;
附图5为加组氨酸缓冲液的开始时的HPLC谱图;
附图6为加组氨酸缓冲液的结束时的HPLC谱图;
附图7为加8%蔗糖的开始时的HPLC谱图;
附图8为加8%蔗糖的结束时的HPLC谱图;
附图9为加4%甘露醇的开始时的HPLC谱图;
附图10为加4%甘露醇的结束时的HPLC谱图;
附图11为各实验组的眼底彩照和荧光造影晚期图片;
附图12为光斑渗漏平均分与剂量关系图。
具体实施方式
下面结合实施例对本发明作进一步的解释。并不因此将本发明限制在所述的实施例范围中。文中所述“%”,若无特殊说明,均为质量百分比。
实施例1
乙磺酸尼达尼布对大鼠脉络膜新生血管的药效学研究
SPF级BN大鼠,雌雄各半,采用眼底激光光凝法造模,造模当天为D0,造模成功后(D8)选择眼底激光光斑的荧光渗漏平均分相近的动物32只,将其随即分为8组,每组4只,雌雄各半,第一组为模型组,不给药;第二组为阳性对照组,动物双眼经玻璃体腔单次注射给予阳性对照药(已上市治疗老年黄斑变性药品),剂量为50μg/眼,每天6次;第三组为给药组,D8~D15动物双眼滴眼给予乙磺酸尼达尼布125μg/眼,每天6次;第四组为给药组,D8~D15动物双眼滴眼给予乙磺酸尼达尼布25μg/眼,每天6次;第五组为给药组,D8~D15动物双眼滴眼给予乙磺酸尼达尼布5μg/眼,每天6次。第六组为给药组,D8~D15动物双眼滴眼给予乙磺酸尼达尼布2.5μg/眼,每天6次。第七组为给药组,D8~D15动物双眼滴眼给予乙磺酸尼达尼布0.5μg/眼,每天6次。第八组为给药组,D8~D15动物双眼滴眼给予乙磺酸尼达尼布0.1μg/眼,每天6次。
所有动物在给药前1天、给药后8天进行眼底照相及FFA检测。根据荧光渗漏程度对大鼠CNV程度进行评级,评级结果以评价大鼠CNV模型建立情况和给药对大鼠CNV的影响。结果见图11。
第三组实验动物均出现了角膜混浊的不良反应,第四组个别动物出现了角膜混浊的不良反应,其余各组动物均没有出现不良反应。
各级光斑比率
给药前1天,各给药组的各级光斑比率与模型组相比均无明显差异(p>0.05)。
给药后,与同期模型组相比,阳性对照组和第三、四、五、六组的3级光斑比率均显著下降(p≤0.05),第七组和第八组与模型组间的差异无统计学意义,第三、四、五、六组的1级光斑比率均升高(p≤0.05),阳性对照组和第七组、第八组与模型组间的差异无统计学意义,各组0级、2级光斑比率均无明显差异(p>0.05),提示光凝1周后给予阳性对照品或第三、四、五、六组的供试品进行干预,给药干预后对大鼠的CNV均具有明显的抑制作用;与同期阳性对照组相比,第三、四、五、六组的3级光斑率均降低(其中,第五组显著下降,p≤0.05),1级光斑率均升高(其中,第五组显著上升,p≤0.05),其余各组0级、2级光斑比率均无明显差异(p>0.05),提示第五组对大鼠CNV渗漏的抑制作用略强于阳性对照组。
光斑渗漏平均分
给药前1天,各给药组的光斑渗漏平均分与模型组相比均无明显差异(p>0.05)。
给药后,与同期模型组相比,阳性对照组和第三、四、五、六组的光斑渗漏平均分均下降(p≤0.05),第七组和第八组与模型组间的差异无统计学意义,表明光凝后1周给药,阳性对照品或第三、四、五、六组的供试品对大鼠CNV的渗漏均有明显的抑制作用,且在药后作用就很明显;与同期阳性对照组相比,仅第五组的光斑渗漏平均分显著下降(p≤0.05),提示第五组对大鼠CNV渗漏的抑制作用可能略强于阳性对照组,结果见图12。
综上所述,从各级光斑比率和光斑渗漏平均分结果来看,给予50μg/眼的阳性对照药单次玻璃体腔注射、连续滴眼125、25、5、2.5、0.5μg/眼给药,激光光凝诱导的大鼠CNV均可被抑制,连续滴眼25μg/眼与阳性对照药50μg/眼单次注射给药对大鼠CNV的抑制作用相近,连续滴眼125、5、2.5μg/眼较阳性对照药单次注射对大鼠CNV的抑制作用略强,但是125μg/眼的剂量组存在较大的不良反应,因此这一组实验结果不作为可接受的有效范围。
实施例2:缓冲液的选择
乙磺酸尼达尼布水溶液在酸性条件下相对稳定。结合滴眼剂可用的pH范围(5.0-9.0),考察了缓冲范围在5.0-6.0之间的醋酸缓冲液(醋酸-醋酸钠),柠檬酸缓冲液(柠檬酸-柠檬酸钠)和组氨酸缓冲液(组氨酸-盐酸组氨酸),实验数据见表1,并在实验数据基础上选择醋酸缓冲液。
表1
实施例3:渗透压调节剂的选择
考虑到滴眼剂是局部给药,需要维持一定的渗透压,因此考察了常用的等渗调节剂,包括0.9%氯化钠,8%蔗糖和4%甘露醇,实验数据参见表2。从制剂的溶解度和稳定性角度考虑考察选择甘露醇和蔗糖。
表2
实施例4
该实施例是制备尼达尼布滴眼剂,每1L尼达尼布滴眼剂(500瓶)含:
乙磺酸尼达尼布 0.5g
甘露醇 40g
pH=5.5的醋酸缓冲液(浓度为10mM) 1L
取乙磺酸尼达尼布(测HPLC,如图1),加入适量醋酸缓冲液(取样测HPLC,图2),加入甘露醇,充分搅拌至全溶,然后过滤除菌,分装即得。
该滴眼剂的pH为5.0-5.5。
储存条件:2~8℃条件下避光保存。
实施例5
该实施例是制备尼达尼布滴眼剂,每1L尼达尼布滴眼剂(500瓶)含:
取乙磺酸尼达尼布,加入适量醋酸缓冲液,加入蔗糖和苯扎氯胺,充分搅拌至全溶,然后过滤除菌,分装即得。
该滴眼剂的pH为5.0-5.5。
储存条件:2~8℃条件下避光保存。
实施例6
该实施例是制备尼达尼布冻干滴眼剂,每1L尼达尼布滴眼剂(500瓶)含:
乙磺酸尼达尼布 0.5g
甘露醇 40g
注射用水 1L
冻干制剂的制法可如下进行:
取乙磺酸尼达尼布,加入甘露醇和注射用水,充分搅拌至全溶,然后过滤除菌,分装到小瓶,进行冻干。冻干包括以下步骤:
步骤1:预冻阶段:设置隔板温度为-40℃,保持3小时;
步骤2:升华干燥阶段:设置隔板温度为-10℃,前箱压力10Pa,保持10小时;
步骤3:解析干燥阶段:设置隔板温度为10℃,前箱压力10Pa,保持10小时;
步骤4:解析干燥阶段后,真空压塞,得到尼达尼布冻干粉针剂。
该尼达尼布冻干粉针剂的pH为5.0-5.5。
使用时用配套的复溶液溶解给药即可,复溶液为pH=5.5,10mM醋酸缓冲液。
Claims (8)
1.一种预防或治疗脉络膜新生血管形成的液体滴眼剂,其特征在于:所述的液体滴眼剂包括活性成分,以及药学上可接受的辅料,所述的液体滴眼剂的pH为5.0~6.0,所述的活性成分为尼达尼布或其盐或其溶剂合物,所述的活性成分的质量百分比浓度为0.005%~10%,所述的辅料包括缓冲剂和渗透压调节剂,所述的缓冲剂为醋酸缓冲剂,所述的醋酸缓冲剂的浓度为5~15mM,所述的醋酸缓冲剂以pH5.0~6.0的醋酸缓冲液的形式投料,所述的渗透压调节剂为甘露醇和/或蔗糖,所述的甘露醇和/或蔗糖的质量百分比浓度为1%~10%。
2.根据权利要求1所述的液体滴眼剂,其特征在于:所述的辅料还包括粘度调节剂、防腐剂、表面活性剂、螯合剂、抗氧剂中的一种或多种。
3.根据权利要求2所述的液体滴眼剂,其特征在于:所述的液体滴眼剂包括质量浓度为0.001%~0.01%的所述的防腐剂。
4.根据权利要求3所述的液体滴眼剂,其特征在于:所述的防腐剂为苯扎氯铵。
5.一种预防或治疗脉络膜新生血管形成的冻干滴眼剂,其特征在于:所述的冻干滴眼剂包括独立包装的冻干粉和复溶液,所述的冻干粉包括活性成分,以及药学上可接受的辅料,所述的活性成分为尼达尼布或其盐或其溶剂合物,所述的辅料包括赋形剂,所述的赋形剂为甘露醇和/或蔗糖,所述的冻干粉中所述的活性成分与所述的甘露醇和/或蔗糖的质量比为1:50~200,所述的复溶液的pH为5.0~6.0,所述的复溶液包括浓度为5~20mM的醋酸缓冲剂。
6.根据权利要求5所述的冻干滴眼剂,其特征在于:所述的冻干粉中的辅料还包括粘度调节剂、防腐剂、表面活性剂、螯合剂、抗氧剂中的一种或多种;所述的复溶液中还包括粘度调节剂、防腐剂、表面活性剂、螯合剂、抗氧剂中的一种或多种。
7.根据权利要求5所述的冻干滴眼剂,其特征在于:所述的冻干粉的制备方法包括依次进行的如下步骤:
步骤(1)、将所述的活性成分、所述的赋形剂和水搅拌溶解,然后过滤除菌分装;
步骤(2)、预冻阶段:设置隔板温度为-10~-50℃,保持1~6小时;
步骤(3)、升华干燥阶段:设置隔板温度为0~-40℃,前箱压力1~200Pa,保持5~30小时;
步骤(4)、解析干燥阶段:设置隔板温度为0~40℃,前箱压力1~200Pa,保持5~30小时;
步骤(5)、解析干燥阶段后,真空压塞,得到所述的冻干粉。
8.根据权利要求1至4中任一项所述的液体滴眼剂、或权利要求5至7中任一项所述的冻干滴眼剂,其特征在于:所述的液体滴眼剂、或所述的冻干滴眼剂避光保存于2~8℃条件下。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610849023 | 2016-09-26 | ||
CN2016108490239 | 2016-09-26 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107865821A CN107865821A (zh) | 2018-04-03 |
CN107865821B true CN107865821B (zh) | 2021-07-02 |
Family
ID=61689743
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710872258.4A Active CN107865821B (zh) | 2016-09-26 | 2017-09-25 | 一种预防或治疗脉络膜新生血管形成的制剂 |
Country Status (5)
Country | Link |
---|---|
US (1) | US10772885B2 (zh) |
EP (1) | EP3515444A4 (zh) |
JP (1) | JP7018939B2 (zh) |
CN (1) | CN107865821B (zh) |
WO (1) | WO2018054077A1 (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11278546B2 (en) | 2016-07-22 | 2022-03-22 | Aiviva Biopharma, Inc. | Multikinase inhibitors and uses in ocular fibrosis |
WO2019197961A1 (en) * | 2018-04-09 | 2019-10-17 | Intas Pharmaceuticals Ltd. | Pharmaceutical composition of nintedanib esylate |
CN117598989A (zh) | 2018-08-28 | 2024-02-27 | 拨云生物医药科技(广州)有限公司 | 多激酶抑制剂的乳液制剂 |
EP3840730B1 (en) * | 2018-12-11 | 2023-09-20 | Disruption Labs Inc. | Compositions for the delivery of therapeutic agents and methods of use and making thereof |
CN109908328A (zh) * | 2019-03-25 | 2019-06-21 | 华南理工大学 | 纳米透皮技术用于改善眼睛干眼症的眼贴及其制备方法 |
CN115645420A (zh) * | 2021-07-07 | 2023-01-31 | 苏州普乐康医药科技有限公司 | 甘露糖及其药用衍生物在制备预防和/或治疗年龄相关性黄斑变性的药物中的应用 |
WO2024037982A1 (en) | 2022-08-16 | 2024-02-22 | Boehringer Ingelheim International Gmbh | Pharmaceutical formulations of nintedanib for intraocular use |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101433519A (zh) * | 2008-12-19 | 2009-05-20 | 沈阳药科大学 | 阿奇霉素滴眼剂及其制备方法 |
CN104884049A (zh) * | 2012-11-08 | 2015-09-02 | 克莱尔塞德生物医学股份有限公司 | 用于在人类受试者中治疗眼部疾病的方法和装置 |
CN108295072A (zh) * | 2015-12-09 | 2018-07-20 | 瑞阳(苏州)生物科技有限公司 | 尼达尼布防治眼部疾病的用途 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4228195B2 (ja) | 2002-02-22 | 2009-02-25 | 参天製薬株式会社 | 微粒子結膜下投与ドラッグデリバリーシステム |
CN1376463A (zh) * | 2002-03-29 | 2002-10-30 | 沈阳药科大学 | 双硫伦包合物滴眼剂及其制备方法 |
DE10233500A1 (de) | 2002-07-24 | 2004-02-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel |
ES2384060B1 (es) * | 2010-03-24 | 2013-09-23 | Lipotec S.A. | Cápsulas de nanopartículas lipídicas. |
CA2877710A1 (en) | 2012-06-25 | 2013-12-19 | Bayer Healthcare Llc | Topical ophthalmological pharmaceutical composition containing pazopanib |
MX2016003566A (es) | 2013-09-20 | 2016-06-02 | Santen Pharmaceutical Co Ltd | Composicion que contiene polietilen glicol. |
WO2016178064A1 (en) | 2015-05-06 | 2016-11-10 | Suven Life Sciences Limited | Polymorph of nintedanib ethanesulphonate, processes and intermediates thereof |
KR20240043821A (ko) * | 2015-06-06 | 2024-04-03 | 클라우드브레이크 테라퓨틱스, 엘엘씨 | 익상편을 치료하기 위한 조성물 및 방법 |
TWI664965B (zh) * | 2015-06-22 | 2019-07-11 | 新源生物科技股份有限公司 | 酪胺酸激酶抑制劑之眼用調配物、其使用方法、及其製備方法 |
CN106902117A (zh) | 2015-12-23 | 2017-06-30 | 瑞阳(苏州)生物科技有限公司 | 一种预防或治疗脉络膜新生血管形成的药物 |
-
2017
- 2017-05-19 WO PCT/CN2017/084994 patent/WO2018054077A1/en unknown
- 2017-05-19 US US16/336,204 patent/US10772885B2/en active Active
- 2017-05-19 JP JP2019516537A patent/JP7018939B2/ja active Active
- 2017-05-19 EP EP17852151.4A patent/EP3515444A4/en active Pending
- 2017-09-25 CN CN201710872258.4A patent/CN107865821B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101433519A (zh) * | 2008-12-19 | 2009-05-20 | 沈阳药科大学 | 阿奇霉素滴眼剂及其制备方法 |
CN104884049A (zh) * | 2012-11-08 | 2015-09-02 | 克莱尔塞德生物医学股份有限公司 | 用于在人类受试者中治疗眼部疾病的方法和装置 |
CN108295072A (zh) * | 2015-12-09 | 2018-07-20 | 瑞阳(苏州)生物科技有限公司 | 尼达尼布防治眼部疾病的用途 |
Also Published As
Publication number | Publication date |
---|---|
JP2019534870A (ja) | 2019-12-05 |
CN107865821A (zh) | 2018-04-03 |
JP7018939B2 (ja) | 2022-02-14 |
US10772885B2 (en) | 2020-09-15 |
US20190224194A1 (en) | 2019-07-25 |
EP3515444A4 (en) | 2020-06-03 |
WO2018054077A1 (en) | 2018-03-29 |
EP3515444A1 (en) | 2019-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107865821B (zh) | 一种预防或治疗脉络膜新生血管形成的制剂 | |
JP7475395B2 (ja) | 異常な新生血管形成を伴う眼疾患を処置するためにニンテダニブを使用する組成物および方法 | |
ES2399045T3 (es) | Combinación de brimonidina y timolol para uso oftálmico tópico | |
TWI764996B (zh) | 含西里帕格之醫藥組成物 | |
US20130252988A1 (en) | Compositions and methods for treating myelofibrosis | |
WO2007112675A1 (fr) | Protéine de fusion du récepteur du vegf et son utilisation | |
US9393307B2 (en) | Caspofungin composition | |
JP2018505209A (ja) | プラミノーゲンを含む医薬組成物及びその使用 | |
US20140235678A1 (en) | Topical Ophthalmological Pharmaceutical Composition containing Sorafenib | |
RU2605288C2 (ru) | Фармацевтическая композиция | |
US20220305083A1 (en) | Stable peptide compositions | |
IE63714B1 (en) | Pharmaceutical compositions of piroxicam in aqueous solutions and process for their preparation | |
WO2012103801A1 (zh) | 一种含有棘白菌素类抗真菌剂米卡芬净的药用组合物及其制备方法和用途 | |
JPH11222441A (ja) | ヒト成長ホルモン含有水性医薬組成物 | |
BR112020002325A2 (pt) | composições farmacêuticas | |
TW202135789A (zh) | 糖尿病黃斑水腫及受損之視覺敏銳度的治療 | |
JPH0558906A (ja) | シクロスポリン点眼製剤 | |
JPH06247872A (ja) | 高濃度tcf製剤 | |
van Sorge et al. | Flurbiprofen, S (+), eyedrops: formulation, enantiomeric assay, shelflife and pharmacology | |
JPH08231403A (ja) | アルギニンバソプレシン拮抗薬を含有する安定な水溶液 | |
WO2019191200A1 (en) | Method and formulation for producing anesthesia of internal aspect of eye wall by topical application | |
EP4342453A1 (en) | Eye drop composition for treating dry eye syndrome containing recoflavone and method for preparing same | |
JP2628020B2 (ja) | 医薬製剤用水溶液 | |
WO2022034545A1 (en) | Etelcalcetide formulations for parenteral use | |
CN117503702A (zh) | 一种含环孢素的组合物、纳米胶束、其制备方法及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |